Phase 3 LSD results drive 55% pop; psilocybin data next catalyst.
Definium Therapeutics surged 55% today on positive Phase 3 LSD-depression results, with more catalysts ahead from psilocybin data expected after summer.
The total addressable market is huge, and existing treatments are weak. Positive Phase 3 results for the LSD-like product for depression drove a 55% surge. Psilocybin results expected after summer could reprice the stock higher.
"Is The Oil Still Flowing? w/ Andreas Steno | Macro Mondays"